Süleyman Arslan

Süleyman Arslan

Auto-generated profile, based on publicly available information

Süleyman Arslan

İnönü University, Turgut Özal Medical Center, Adult Hematology Department

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2023 in Journal of Clinical Apheresis
Verified
Journal Article
Closed access
AKAhmet Kaya
Ahmet Kaya
MEMehmet Ali Erkurt
Mehmet Ali Erkurt
IKİrFan Kuku
İrFan Kuku
EKEmin KAYA
Emin KAYA
IBİlHami Berber
İlHami Berber
ASAhmet Sarıcı
Ahmet Sarıcı

30 October 2024 in Marmara Medical Journal
Verified
Journal Article
Closed access
PDF file
AKAhmet Kaya
Ahmet Kaya
MEMehmet Ali Erkurt
Mehmet Ali Erkurt
IKİrFan Kuku
İrFan Kuku
EKEmin KAYA
Emin KAYA
IBİlHami Berber
İlHami Berber
FYFatma Hilal Yagın
Fatma Hilal Yagın
Objective: Chronic graft versus host disease (cGVHD) develops after allogeneic hematopoietic cell transplantation, when immune cells from a non-identical donor initiate an immune reaction against the transplant recipient. Extracorporeal photopheresis (ECP) can be used in combination with prednisone in steroid-resistant cGVHD. In this study, the effect of ECP use on survival in cGVHD was examined. Patients and Methods: Twenty-six patients who were followed up in the adult Hematology Clinic of Inonu University Turgut Ozal Medical Center for cGVHD were included in the study. Stem cell transplantation and ECP application parameters that may affect the survival of the patients were examined. Results: The degree of involvement in cGVHD affects survival. Involvements with clinical and laboratory scores of 2 and above according to the National Institutes of Health consensus criteria, significantly reduced survival. The development time of cGVHD was found to be associated with survival, and that it had a positive impact on survival, especially when the disease developed after 220 days after the transplantation. It was observed that steroid dose taken during ECP, patient age and cGVHD prophylaxis used affected survival. Conclusion: The use of ECP may be effective in survival, especially, in patients who develop cGVHD, 220 days after allogeneic transplantation. Concurrent use of steroids with ECP affects survival.

12 January 2025 in Journal of Health Sciences and Medicine
Verified
Journal Article
Open access
PDF file
NBNurcan Kırıcı Berber
Nurcan Kırıcı Berber
ZDZeliha Korkmaz Dişli
Zeliha Korkmaz Dişli
LDLeman Acun Delen
Leman Acun Delen
LGLale Şahin Gür
Lale Şahin Gür
AYAzize Yetişgen
Azize Yetişgen
IBİlHami Berber
İlHami Berber
Aims: This study aims to evaluate the efficacy of the serum lactate/albumin ratio (LAR) as a prognostic marker in patients with ventilator-associated pneumonia (VAP) who are hospitalized in the intensive care unit (ICU). Methods: This single-center retrospective observational clinical study was conducted between January 1, 2022, and October 1, 2024. The study group comprised 58 patients admitted to the ICUs of Malatya Training and Research Hospital, Turkiye, with intubation but without a diagnosis of pneumonia at the time of admission. These patients were diagnosed with VAP 48 hours after intubation. The serum LAR was calculated within the first 24 hours after admission to the ICU and correlated with mortality and morbidity. Results: The mean age of the patients was 68 years, with the majority being over 65 years of age. Of the 58 patients included in the study, 43 (74.1%) ultimately succumbed to their illness. The LAR of those who died in the study was significantly higher than that of those who survived. The LAR was identified as a reliable predictor, exhibiting a sensitivity of 83.7% and a specificity of 60% when a cutoff value of 1.13 was applied. The survival time of patients with a LAR of ≤1.13 was significantly longer than that of patients with a ratio of >1.13. Conclusion: In our study, the mortality prediction performance of the LAR in patients with VAP was superior to that of the serum lactate level or serum albumin level alone. Therefore, the LAR may be a useful and readily available prognostic factor for early risk stratification of VAP patients.

26 February 2023 in Journal of Current Hematology & Oncology Research
Verified
Journal Article
Open access
AKAhmet Kaya
Ahmet Kaya
IBİlHami Berber
İlHami Berber
IKİrFan Kuku
İrFan Kuku
MEMehmet Ali Erkurt
Mehmet Ali Erkurt
EKEmin KAYA
Emin KAYA
ASAhmet Sarıcı
Ahmet Sarıcı
Aims: In this study, we aim to discover if there is a difference between COVID 19 antibody level in hematological patients taking conventional chemotherapy and tyrosin kinase inhibitors. Methods: COVİD 19 IgG levels were measured using the QuantiCOR anti-SARS-CoV-2 IgG ELISA test kit on 74 patients who received chemotherapy and used tyrosine kinase inhibitors in the adult hematology clinic of Turgut Özal Medical Center between May 2019 and January 2022. Age, height, weight, badimeks index of the patients were measured, the doses and durations of vaccine use, the time between the first vaccine and the second vaccine, how long after the first vaccine antibodies were checked, and vaccine-related side effects were recorded. Collected data Statistical analysis was performed using Python 3.9 and IBM SPSS Statistics for Windows version 26.0 (New York; USA). Results: Antibody levels of the patients were significantly higher in the healthy control group than in the groups that received chemotherapy and tyrosine kinase inhibitors. Antibody levels of female patients in the control group were higher than male patients. Antibody levels of the patient groups receiving chemotherapy and tyrosine kinase inhibitor were not found to differ between the two groups. When the patients receiving B lymphocyte suppressing chemotherapy in the chemotherapy group were compared with the control group, antibody levels were found to be higher in the control group. Conclusion: COVID 19 vaccination in hematological cancers did not produce adequate antibody response, especially in patients receiving chemotherapy or tyrosine kinase inhibitors.